Need help with insurance? Call 855-507-2622
In 2026, the FDA (Food and Drug Administration) has transitioned from a passive observer of the cannabis industry to its primary federal architect. Following the December 2025 Executive Order to move cannabis to Schedule III, the FDA is currently standardizing the “Pharmaceutical Pathway” for botanical medicine.